Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for treatments targeting chemotherapy-induced peripheral neuropathy has experienced robust expansion recently, projected to advance from $1.75 billion in 2025 to $1.86 billion in 2026, reflecting a compound annual growth rate of 6.2%. This historical growth trajectory is underpinned by several key factors, including the escalating prescription of neurotoxic chemotherapy drugs, an increase in cancer patient survival rates, heightened awareness surrounding the adverse effects of chemotherapy, the accessibility of therapies aimed at alleviating symptoms, and the overall expansion of cancer care facilities.
The market for treating chemotherapy-induced peripheral neuropathy is poised for significant expansion in the coming years, projected to reach $2.37 billion by 2030 with a CAGR of 6.2%. This anticipated growth during the forecast period is fueled by several key factors, including heightened investment in specialized neuropathy treatments, a greater emphasis on individualized supportive care within oncology, an increase in clinical trials for CIPN medications, a growing need for treatments that enhance patient quality of life, and advancements in diagnosing the condition using biomarkers. Dominant trends expected to shape this market over the forecast period involve a concentrated effort on developing neuroprotective drugs, a broader acceptance of combination therapy strategies, a stronger push for early identification and effective symptom management, the proliferation of tailored treatment plans, and intensified clinical investigation into managing CIPN.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp
Chemotherapy Induced Peripheral Neuropathy Treatment Market Industry Drivers: What Is Driving Revenue Growth?
The escalating incidence of cancer globally is anticipated to serve as a primary catalyst for the expansion of the treatment market for chemotherapy-induced peripheral neuropathy. Peripheral neuropathy, a distressing adverse effect that can emerge from specific chemotherapy regimens administered for cancer care, is seeing increased attention as cancer diagnoses rise. For example, data from the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that an estimated 165,000 new cancer diagnoses were made in Australia in 2023, translating to more than 450 individuals diagnosed daily, with males accounting for approximately 55% of these new cases. Thus, the growing global burden of cancer is directly fueling the demand for treatments addressing chemotherapy-induced peripheral neuropathy.
Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Landscape: Which Areas Lead Market Development?
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –
1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics
Subsegments:
1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine
2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine
4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10
5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies
#Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Trends: What Is Influencing The Future Outlook?
AlgoTx, a clinical-stage entity dedicated to managing intricate pain conditions, announced in March 2023 that the FDA has greenlit their Investigational New Drug Application for ATX01, a groundbreaking Phase 2 candidate. This novel therapy is slated for use in patients suffering from erythromelalgia. Concurrently, the ATX01 for the Pain of Chemotherapy (ACT) trial, investigating chemotherapy-induced peripheral neuropathy (CIPN), has enrolled its initial participants. Both of these initiatives have been granted fast-track status by the U.S. Food and Drug Administration, underscoring the companies’ dedication to advancing innovative treatments within the chemotherapy-induced peripheral neuropathy market to enhance patient outcomes and solidify their competitive standing.
Chemotherapy Induced Peripheral Neuropathy Treatment Market Industry Leaders And Market Competition
Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.
Access The Complete Chemotherapy Induced Peripheral Neuropathy Treatment Market Report:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional Analysis And Leading Geography
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model